select trial glp 1 EFFECT OF THE GLP-1 RECEPTOR AGONIST SEMAGLUTIDE ON TOTAL CARDIOVASCULAR EVENTS IN PATIENTS WITH CARDIOVASCULAR DISEASE AND OVERWEIGHT OR OBESITY BUT NO DIABETES IN THE Disappointing GLP-1 Results in Alzheimer's

The key point here is that GLP-1 medications do not just reduce how much you eat

Coffee consumption and risk of type 2 diabetes

After all, GLP-1 is a hormone so perhaps GLP-1RAs (tirzepatide in this case) should be part of a comprehensive hormone therapy

Yang, W

According to the results of both DAPA-HF [13] and EMPEROR-R [14], the FDA have approved both dapagliflozin and empagliflozin to reduce the risk of CV death or hospitalization for HF in adults with HF and reduced ejection fraction regardless of whether they have diabetes

Patients should be counselled before starting treatment that gastrointestinal symptoms are common, particularly in the early weeks, and that they often diminish over time as the body adjusts to the medication